This company has been acquired
La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
CNCE Aperçu des actions
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
Concert Pharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$8.37 |
| Plus haut sur 52 semaines | US$8.55 |
| Plus bas sur 52 semaines | US$2.66 |
| Bêta | 0.52 |
| 1Variation sur 1 mois | 0% |
| Variation sur 3 mois | 92.86% |
| Variation sur 1 an | 203.26% |
| 3Variation sur 3 ans | -9.22% |
| Variation sur 5 ans | -64.31% |
| Évolution depuis l'introduction en bourse | -40.97% |
Nouvelles et mises à jour récentes
Recent updates
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
CinCor Pharma hits 52-week high on data for antihypertensive agent
Aug 08Concert Pharmaceuticals: A Balanced Risk/Reward
Jun 15We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
Jun 04Concert Pharmaceuticals: A Speculative Buy For Their Alopecia Areata Drug
Jun 03Concert Pharmaceuticals (NASDAQ:CNCE) Is In A Good Position To Deliver On Growth Plans
Jan 11Here's Why We're Watching Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Aug 27We're Keeping An Eye On Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Rate
May 25Concert Pharma EPS beats by $0.02
May 04Concert Pharmaceuticals' (NASDAQ:CNCE) Stock Price Has Reduced 70% In The Past Three Years
Feb 27Concert Pharma fails in mid-stage study for CTP-692 Schizophrenia
Feb 01Here's Why We're Not Too Worried About Concert Pharmaceuticals' (NASDAQ:CNCE) Cash Burn Situation
Jan 23How Much Of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Do Insiders Own?
Dec 19
A Look At Concert Pharmaceuticals' (NASDAQ:CNCE) Share Price Returns
Nov 23Concert Pharma EPS beats by $0.15
Nov 05Concert Pharma launches late-stage study of CTP-543 in hair loss disorder
Nov 03Rendement pour les actionnaires
| CNCE | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -0.1% | 0.6% | 0.8% |
| 1Y | 203.3% | 27.4% | 38.4% |
Rendement vs Industrie: CNCE exceeded the US Biotechs industry which returned 8.9% over the past year.
Rendement vs marché: CNCE exceeded the US Market which returned -5.5% over the past year.
Volatilité des prix
| CNCE volatility | |
|---|---|
| CNCE Average Weekly Movement | 10.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.0% |
Cours de l'action stable: CNCE's share price has been volatile over the past 3 months.
Volatilité au fil du temps: CNCE's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Concert Pharmaceuticals, Inc. Résumé des fondamentaux
| CNCE statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$520.71m |
| Bénéfices(TTM) | -US$126.68m |
| Recettes(TTM) | US$32.04m |
16.3x
Ratio P/S-4.1x
Ratio P/ELe site CNCE est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CNCE compte de résultat (TTM) | |
|---|---|
| Recettes | US$32.04m |
| Coût des recettes | US$102.70m |
| Marge brute | -US$70.66m |
| Autres dépenses | US$56.02m |
| Les revenus | -US$126.68m |
Derniers bénéfices déclarés
Sep 30, 2022
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.04 |
| Marge brute | -220.53% |
| Marge bénéficiaire nette | -395.36% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CNCE?
Voir les performances historiques et les comparaisons